Cited by 70Stress Responses and CortisolNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress

Open access
Hains, Avis Brennan, Yabe, Yoko, Arnsten, Amy F.T.·2015·Neurobiology of Stress

Abstract

The prefrontal cortex (PFC) provides top-down regulation of behavior, cognition, and emotion, including spatial working memory. However, these PFC abilities are greatly impaired by exposure to acute or chronic stress. Chronic stress exposure in rats induces atrophy of PFC dendrites and spines that correlates with working memory impairment. As similar PFC grey matter loss appears to occur in mental illness, the mechanisms underlying these changes need to be better understood. Acute stress exposure impairs PFC cognition by activating feedforward cAMP-calcium- K+ channel signaling, which weakens synaptic inputs and reduces PFC neuronal firing. Spine loss with chronic stress has been shown to involve calcium-protein kinase C signaling, but it is not known if inhibiting cAMP signaling would similarly prevent the atrophy induced by repeated stress. The current study examined whether inhibiting cAMP signaling through alpha-2A-adrenoceptor stimulation with chronic guanfacine treatment would protect PFC spines and working memory performance during chronic stress exposure. Guanfacine was selected due to 1) its established effects on cAMP signaling at post-synaptic alpha-2A receptors on spines in PFC, and 2) its increasing clinical use for the treatment of pediatric stress disorders. Daily guanfacine treatment compared to vehicle control was found to prevent dendritic spine loss in layer II/III pyramidal neurons of prelimbic PFC in rats exposed to chronic restraint stress. Guanfacine also protected working memory performance; cognitive performance correlated with dendritic spine density. These findings suggest that chronic guanfacine use may have clinical utility by protecting PFC gray matter from the detrimental effects of stress.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ynstr.2015.01.001

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Guanfacine can protect PFC circuits from stress exposure, including preventing atrophy due to chronic stress exposure.

    “Evidence from both in vivo and in vitro studies show that guanfacine can protect PFC circuits from stress exposure, including preventing atrophy due to chronic stress exposure.”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Hains et al., 2015

    The Abstract and Discussion (Summary and evaluation of data; page unavailable) report that daily guanfacine prevented stress-related PFC dendritic spine loss and protected working memory in rats. The Introduction reports in vitro findings of spine growth and spinophilin enrichment, but does not say those cell-culture studies tested protection from stress exposure. Thus the chronic-stress protection is supported by the in vivo study, not by both types of study as the citing sentence states. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Daily guanfacine administration prevented spine loss and working memory deficits.

    “and daily guanfacine administration prevented spine loss and working memory deficits (Hains et al., 2015), which may help to explain its utility in treating stress-related disorders.”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Hains et al., 2015

    The Discussion (Summary and evaluation of data) says daily guanfacine protected spine density and working-memory performance in rats exposed to repeated restraint stress. It also says cognitive performance did not completely normalize, so describing working-memory deficits as prevented overstates the result. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Inhibition of PKC or PKA signaling can prevent loss of mPFC dendritic spines and working memory abilities during chronic stress exposure.

    “Research in rats by Avis Hains has shown that inhibition of PKC or PKA signaling can prevent the loss of mPFC dendritic spines and working memory abilities during chronic stress exposure (Hains et al., 2009, Hains et al., 2015), suggesting that the sustained weakening of synaptic connectivity via K+ channel opening contributes to spine loss.”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Hains et al., 2015

    The Introduction reports that inhibiting calcium-PKC signaling rescued spine density and working memory during repeated stress, citing Hains et al. (2009). The Discussion reports that guanfacine protected both outcomes in stressed rats, but the 2015 study tested alpha-2A-adrenoceptor stimulation to inhibit cAMP signaling, not PKA inhibition specifically. The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Chronic stress reduces PFC spine density in vehicle-treated rats but not in those receiving daily guanfacine treatment.

    “Chronic stress (Str) exposure reduces PFC spine density in vehicle-treated rats, but not in those receiving daily guanfacine treatment.”
  • Daily treatment with guanfacine preserves working memory performance in chronically stressed rats.

    “and preserved working memory performance (Hains et al., 2015)”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

  1. Arnsten A.F.T. Stress signaling pathways that impair prefrontal cortex structure and function Nat. Rev. Neurosci. 10 2009 410 422 PMCID: PMC2907136 19455173 PMC2907136
  2. Breier A. Wolkowitz O. Pickar D. Stress and schizophrenia: advances in neuropsychiatry and psychopharmacology Tamminga C. Schult S. Schizophrenia Research vol. 1 1991 Raven Press, Ltd. New York
  3. Engberg G. Eriksson E. Effects of alpha-2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in EEDQ-treated rats Naunyn- Schmiedeb. Arch. Pharmacol. 343 1991 472 477 1652697
  4. Mazure C.M. Does Stress Cause Psychiatric Illness? 1995 American Psychiatric Press Washington, D.C.
  5. McKee S. Potenza M. Kober H. Sofouglu M. Arnsten A. Picciotto M. Weinberger A. Ashare R. Sinha R. α2A-AR agonist shows promise for nicotine dependence: enhancing self control during stress J Psychopharmacology 2014 (in press)

Cited by

Sorted by citations

Authors
Hains, A. B., Yabe, Y., & Arnsten, A. F. T.
Affiliations
Yale University (US)
Corresponding author
Arnsten, Amy F.T.
Venue
Neurobiology of Stress
Publisher
Elsevier BV
Published
2015
Volume
2
Pages
1-9
ISSN
2352-2895 (ISSN-L)
OpenAlex
W2070844974
Cited by
70
References
70
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 14 · 2020: 8 · 2019: 6 · 2018: 2 · 2017: 8 · 2016: 6 · 2015: 4
FWCI
3.47
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Stress (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • PHS (RL1AA017536, U54RR024350)
  • Shire Pharmaceuticals
Topics
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
guanfacine, chronic stress, prefrontal cortex, dendritic spines, dendritic atrophy, working memory, cAMP signaling, prelimbic cortex, restraint stress, synaptic plasticity, gray matter loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review